

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653lxm

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 Feb 24 PCTGEN now available on STN  
NEWS 4 Feb 24 TEMA now available on STN  
NEWS 5 Feb 26 NTIS now allows simultaneous left and right truncation  
NEWS 6 Feb 26 PCTFULL now contains images  
NEWS 7 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results  
NEWS 8 Mar 24 PATDPAFULL now available on STN  
NEWS 9 Mar 24 Additional information for trade-named substances without  
structures available in REGISTRY  
NEWS 10 Apr 11 Display formats in DGENE enhanced  
NEWS 11 Apr 14 MEDLINE Reload  
NEWS 12 Apr 17 Polymer searching in REGISTRY enhanced  
NEWS 13 Jun 13 Indexing from 1947 to 1956 added to records in CA/CAPLUS  
NEWS 14 Apr 21 New current-awareness alert (SDI) frequency in  
WPIDS/WPINDEX/WPIX  
NEWS 15 Apr 28 RDISCLOSURE now available on STN  
NEWS 16 May 05 Pharmacokinetic information and systematic chemical names  
added to PHAR  
NEWS 17 May 15 MEDLINE file segment of TOXCENTER reloaded  
NEWS 18 May 15 Supporter information for ENCOMPAT and ENCOMPLIT updated  
NEWS 19 May 19 Simultaneous left and right truncation added to WSCA  
NEWS 20 May 19 RAPRA enhanced with new search field, simultaneous left and  
right truncation  
NEWS 21 Jun 06 Simultaneous left and right truncation added to CBNB  
NEWS 22 Jun 06 PASCAL enhanced with additional data  
NEWS 23 Jun 20 2003 edition of the FSTA Thesaurus is now available  
NEWS 24 Jun 25 HSDB has been reloaded  
NEWS 25 Jul 16 Data from 1960-1976 added to RDISCLOSURE  
NEWS 26 Jul 21 Identification of STN records implemented  
NEWS 27 Jul 21 Polymer class term count added to REGISTRY  
NEWS 28 Jul 22 INPADOC: Basic index (/BI) enhanced; Simultaneous Left and  
Right Truncation available  
NEWS 29 AUG 05 New pricing for EUROPATFULL and PCTFULL effective  
August 1, 2003  
  
NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT  
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),  
AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 12:36:12 ON 11 AUG 2003

=> file registry  
COST IN U.S. DOLLARS                      SINCE FILE    TOTAL  
   ENTRY    SESSION  
FULL ESTIMATED COST                      0.21    0.21

FILE 'REGISTRY' ENTERED AT 12:36:29 ON 11 AUG 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 8 AUG 2003 HIGHEST RN 563538-18-1  
DICTIONARY FILE UPDATES: 8 AUG 2003 HIGHEST RN 563538-18-1

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP  
PROPERTIES for more information. See STN Note 27, Searching Properties  
in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> s aeararraaaraara/sqep  
      0 AEARRRAAARAARA/SQEP  
      97158 SQL=18  
L1     0 AEARRRAAARAARA/SQEP  
      (AEARRRAAARAARA/SQEP AND SQL=18)

=> s AEARRRAAARAARA/SQsP  
L2     0 AEARRRAAARAARA/SQSP

=> s araarraaaraara/sqsp  
L3     0 ARAARRAARAARARAE/SQSP

=> s ARAARRAARAARARAE/SQeP  
      0 ARAARRAARAARARAE/SQEP  
      97158 SQL=18  
L4     0 ARAARRAARAARARAE/SQEP  
      (ARAARRAARAARARAE/SQEP AND SQL=18)

=> s arraaraarrarae  
L5     0 ARRAARAARRARAE

=> s arraaraarrarae/sqsp or arraaraarrarae/sqep

3 ARRAARAAARRARAEA/SQSP  
 2 ARRAARAAARRARAEA/SQEP  
 40731-SQL=16 - - -  
 2 ARRAARAAARRARAEA/SQEP  
 (ARRAARAAARRARAEA/SQEP AND SQL=16)  
 L6 3 ARRAARAAARRARAEA/SQSP OR ARRAARAAARRARAEA/SQEP

=> s crraaraaarraraea

L7 0 CRRAARAAARRARAEA

=> s CRRAARAAARRARAEA/sqep or CRRAARAAARRARAEA/sqsp

1 CRRAARAAARRARAEA/SQEP  
 40731 SQL=16  
 1 CRRAARAAARRARAEA/SQEP  
 (CRRAARAAARRARAEA/SQEP AND SQL=16)  
 1 CRRAARAAARRARAEA/SQSP  
 L8 1 CRRAARAAARRARAEA/SQEP OR CRRAARAAARRARAEA/SQSP

=> s l6 or l8

L9 4 L6 OR L8

=> file caplus

COST IN U.S. DOLLARS	ENTRY	SINCE FILE SESSION	TOTAL
FULL ESTIMATED COST		142.04	142.25

FILE 'CAPLUS' ENTERED AT 12:39:47 ON 11 AUG 2003  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Aug 2003 VOL 139 ISS 7  
 FILE LAST UPDATED: 10 Aug 2003 (20030810/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l9

L10 2 L9

=> d l10 1-2 all

L10 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN  
 AN 2001:178433 CAPLUS  
 DN 134:217197  
 TI Heparin binding peptides for neutralization of heparin anticoagulant activity without deleterious side-effects  
 IN Harris, Robert B.; Sobel, Michael  
 PA Commonwealth Biotechnologies, Inc., USA  
 SO U.S., 36 pp., Cont.-in-part of U.S. 5,877,153.

CODEN: USXXAM  
DT Patent  
LA English  
IC ICM A61K038-00  
NCL 514013000  
CC 1-8 (Pharmacology)  
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 6200955	B1	20010313	US 1998-166930	19981006
US 5877153	A	19990302	US 1996-660592	19960611
CA 2257614	AA	19971218	CA 1997-2257614	19970603
EP 999219	A2	20000510	EP 1999-119514	19991001
EP 999219	A3	20000524		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

JP 2000136202 A2 20000516 JP 1999-285185 19991006  
PRAI US 1996-660592 A2 19960611  
US 1998-166930 A 19981006

AB Heparin antagonist peptides are disclosed. The heparin-binding peptides of the invention specifically neutralize heparin's conventional anticoagulant properties without causing deleterious hemodynamic side-effects or exacerbation of the proliferative vascular response to injury. More specifically, the heparin-binding compds. of the invention are short-duration drugs to be used in elective or emergency situations which can safely and specifically neutralize heparin's conventional anticoagulant properties without causing deleterious hemodynamic side-effects or exacerbation of the proliferative vascular response to injury.

ST peptide heparin binding anticoagulant neutralization

IT Cell proliferation

Drug delivery systems

Hemostatics

Molecular association

Molecular modeling

Thermodynamics

(heparin binding peptides for neutralization of heparin anticoagulant activity without deleterious side-effects)

IT Oligosaccharides, biological studies

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(pentasaccharides, heparin pentasaccharide unit structure; heparin binding peptides for neutralization of heparin anticoagulant activity without deleterious side-effects)

IT Blood vessel

(smooth muscle; heparin binding peptides for neutralization of heparin anticoagulant activity without deleterious side-effects)

IT Drug delivery systems

(topical; heparin binding peptides for neutralization of heparin anticoagulant activity without deleterious side-effects)

IT 109319-16-6

RL: BSU (Biological study, unclassified); BIOL (Biological study) (K569-I580 peptide; heparin binding peptides for neutralization of heparin anticoagulant activity without deleterious side-effects)

IT 329358-77-2 329358-78-3 329358-79-4 329358-80-7 329358-81-8 329358-82-9 329358-83-0

RL: PRP (Properties)

(Unclaimed; heparin binding peptides for neutralization of heparin anticoagulant activity without deleterious side-effects)

IT 9000-94-6, Antithrombin III

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(and K121-A134 peptide; heparin binding peptides for neutralization of heparin anticoagulant activity without deleterious side-effects)

IT 9005-49-6, Heparin, biological studies-  
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
 (heparin binding peptides for neutralization of heparin anticoagulant activity without deleterious side-effects)

IT 141509-39-9P 267419-40-9P 267419-42-1P 267419-44-3P 267419-45-4P 268539-71-5P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (heparin binding peptides for neutralization of heparin anticoagulant activity without deleterious side-effects)

IT 9004-10-8, Insulin, biological studies 268539-65-7 268539-69-1  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (heparin binding peptides for neutralization of heparin anticoagulant activity without deleterious side-effects)

IT 9002-05-5, Blood coagulation factor Xa  
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
 (heparin binding peptides for neutralization of heparin anticoagulant activity without deleterious side-effects)

IT 329688-19-9  
 RL: PRP (Properties)  
 (unclaimed protein sequence; heparin binding peptides for neutralization of heparin anticoagulant activity without deleterious side-effects)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Anon; WO 9513083 1995 CAPLUS  
 (2) Anon; WO 9747312 1997 CAPLUS  
 (3) Harris; US 5877153 1999 CAPLUS

L10 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1998:13853 CAPLUS

DN 128:93197

TI Novel heparin-binding peptides

IN Harris, Robert B.; Sobel, Michael

PA Commonwealth Biotechnologies, Inc., USA

SO PCT Int. Appl., 61 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K038-00

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1, 34

FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI	WO 9747312	A1	19971218	WO 1997-US9037 19970603
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			

US 5877153 A 19990302 US 1996-660592 19960611  
CA 2257614 AA 19971218 CA 1997-2257614 19970603  
AU-9732167 A1 19980107 AU 1997-32167 19970603  
EP 907368 A1 19990414 EP 1997-927795 19970603  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, FI

JP 2001503018 T2 20010306 JP 1998-501628 19970603  
PRAI US 1996-660592 A 19960611  
WO 1997-US9037 W 19970603

AB The present invention provides heparin antagonist peptides. The heparin-binding peptides of the present invention specifically neutralize heparin's conventional anticoagulant properties without causing deleterious hemodynamic side effects or exacerbation of the proliferative vascular response to injury. More specifically, the heparin-binding compds. of the present invention are short-duration drugs to be used in elective or emergency situations which can safely and specifically neutralize heparin's conventional anticoagulant properties without causing deleterious hemodynamic side effects or exacerbation of the proliferative vascular response to injury.

ST heparin inhibitor peptide sequence

IT Anticoagulants

(inhibitors of; novel heparin-binding peptides for neutralizing the anticoagulant effect of heparin)

IT Protein sequences

(novel heparin-binding peptides for neutralizing the anticoagulant effect of heparin)

IT Peptides, biological studies

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
(novel heparin-binding peptides for neutralizing the anticoagulant effect of heparin)

IT Drug delivery systems

(topical; novel heparin-binding peptides for neutralizing the anticoagulant effect of heparin)

IT Amino acids, biological studies

RL: BOC (Biological occurrence); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)  
(D-; novel heparin-binding peptides for neutralizing the anticoagulant effect of heparin)

IT 200888-86-4D, acetyl and succinyl derivs. 200888-87-5D, acetyl and succinyl derivs. 200888-88-6D, acetyl and succinyl derivs.

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
(novel heparin-binding peptides for neutralizing the anticoagulant effect of heparin)

IT 9005-49-6, Heparin, biological studies

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
(novel heparin-binding peptides for neutralizing the anticoagulant effect of heparin)

IT 9004-10-8, Insulin, biological studies

RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
(novel heparin-binding peptides for neutralizing the anticoagulant effect of heparin)

Connecting via Winsock to Dialog

Logging in to Dialog

Trying 31060000009999...Open

DIALOG INFORMATION SERVICES

PLEASE LOGON:

\*\*\*\*\*

ENTER PASSWORD:

\*\*\*\*\*

Welcome to DIALOG

Dialog level 02.18.00D.

Last logoff: 09aug03 11:19:34

Logon file405 11aug03 11:32:10

\*\*\* ANNOUNCEMENT \*\*\*

\*\*\*

--File 654 - US published applications from March 15, 2001 to the present are now online. Please see HELP NEWS 654 for details.

\*\*\*

--File 581 - The 2003 annual reload of Population Demographics is complete. Please see Help News581 for details.

\*\*\*

\*\*\*

--File 990 - NewsRoom now contains February 2003 to current records.  
File 992 - NewsRoom 2003 archive has been newly created and contains records from January 2003. The oldest months's records roll out of File 990 and into File 992 on the first weekend of each month.  
To search all 2003 records BEGIN 990, 992, or B NEWS2003, a new OneSearch category.

\*\*\*

--Connect Time joins DialUnits' as pricing options on Dialog.  
See HELP CONNECT for information.

\*\*\*

\*\*\*

--SourceOne patents are now delivered to your email inbox as PDF replacing TIFF delivery. See HELP SOURCE1 for more information.

\*\*\*

--Important news for public and academic libraries. See HELP LIBRARY for more information.

\*\*\*

--Important Notice to Freelance Authors--  
See HELP FREELANCE for more information

\*\*\*

NEW FILES RELEASED

\*\*\*World News Connection (File 985)

\*\*\*Dialog NewsRoom - 2003 Archive (File 992)

\*\*\*TRADEMARKSCAN-Czech Republic (File 680)

\*\*\*TRADEMARKSCAN-Hungary (File 681)

\*\*\*TRADEMARKSCAN-Poland (File 682)

\*\*\*

UPDATING RESUMED

\*\*\*

RELOADED

\*\*\*Population Demographics -(File 581)

\*\*\*CLAIMS Citation (Files 220-222)

REMOVED

\*\*\*

>>> Enter BEGIN HOMEBASE for Dialog Announcements <<<  
>>> of new databases, price changes, etc. <<<

\*\*\*\*

\* \* \* \* See HELP NEWS 225 for information on new search prefixes  
and display codes

\*\*\*

\*\*\*

SYSTEM:HOME

Cost is in DialUnits

Menu System II: D2 version 1.7.9 term=ASCII

\*\*\* DIALOG HOMEBASE(SM) Main Menu \*\*\*

Information:

1. Announcements (new files, reloads, etc.)
2. Database, Rates, & Command Descriptions
3. Help in Choosing Databases for Your Topic
4. Customer Services (telephone assistance, training, seminars, etc.)
5. Product Descriptions

Connections:

6. DIALOG(R) Document Delivery
7. Data Star(R)

(c) 2000 The Dialog Corporation plc All rights reserved.

/H = Help      /L = Logoff      /NOMENU = Command Mode

Enter an option number to view information or to connect to an online  
service. Enter a BEGIN command plus a file number to search a database  
(e.g., B1 for ERIC).

? b 410

11aug03 11:32:11 User268147 Session D130.1

\$0.00 0.155 DialUnits FileHomeBase

\$0.00 Estimated cost FileHomeBase

\$0.00 Estimated cost this search

\$0.00 Estimated total session cost 0.155 DialUnits

File 410:Chronolog(R) 1981-2003/Aug

(c) 2003 The Dialog Corporation

Set Items Description

? set hi %%%;set hi %%%

HIGHLIGHT set on as "

HIGHLIGHT set on as "

? b 5, 34, 155, 172

11aug03 11:32:23 User268147 Session D130.2

\$0.00 0.071 DialUnits File410

\$0.00 Estimated cost File410

\$0.04 TELNET

\$0.04 Estimated cost this search

\$0.04 Estimated total session cost 0.226 DialUnits

SYSTEM:OS - DIALOG OneSearch



File 5:Biosis Previews(R) 1969-2003/Aug W1

(c) 2003 BIOSIS

File 34:SciSearch(R) Cited Ref Sci 1990-2003/Aug W1

(c) 2003 Inst for Sci Info

File 155:MEDLINE(R) 1966-2003/Aug W2

(c) format only 2003 The Dialog Corp.

\*File 155: Medline has been reloaded and accession numbers have changed. Please see HELP NEWS 155.

File 172:EMBASE Alert 2003/Aug W2

(c) 2003 Elsevier Science B.V.

#### Set Items Description

7/9/1 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2003 BIOSIS. All rts. reserv.

11032797 BIOSIS NO.: 199799653942

High molecular weight kininogen peptides inhibit the formation of kallikrein on endothelial cell surfaces and subsequent urokinase-dependent plasmin formation.

AUTHOR: Lin Yingzhang; Harris Robert B; Yan Wuyi; McCrae Keith R; Zhang Hong; Colman Robert W(a

AUTHOR ADDRESS: (a)Sol Sherry Thrombosis Res. Cent., Temple Univ. Sch. Med., 3400 N. Broad St., Philadelphia, PA 19\*\*USA

JOURNAL: Blood 90 (2):p690-697 1997

ISSN: 0006-4971

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: A sequence of 31 amino acids (S565-K595) in domain 6 of the light chain of high molecular weight kininogen (HK) has previously been shown to be responsible for the binding of plasma prekallikrein (PK) or kallikrein. To find effective peptides that might block binding between HK and PK on cell surfaces, a new series of synthetic peptides has now been prepared that incorporates portions of this binding domain sequence. For mapping the minimal sequence within HK, these new peptides were tested for their ability to compete with HK for binding PK in a cell-free system and on human umbilical vein endothelial cells (HUVEC). In the former, at pH 7.4, the kds for binding between kallikrein and either D567-K595, S565-P594, D567-S593, or D567-T591 were all similar to that for the binding of S565-K595 (0.2 to 0.4 mu-mol/L), but those for the binding of D568-K595, W569-K595, and D567-P589 were an order of magnitude greater (kd = 2 to 5 mu-mol/L). D567-S586, the shortest chain length of the N- and C-terminal truncation sequences tested, does not effectively compete with kininogen for kallikrein binding (kd = 100 mu-mol/L). These results imply that D567-T591, a 25-residue peptide (HK25c), contains sufficient structural information for binding kallikrein in solution. D567-T591 also is the minimum structural sequence to block binding of kallikrein to HUVEC-bound HK (IC-50 = 50 nmol/L) and to inhibit PK activation to kallikrein on the cell surface (IC-50 = 80 nmol/L). In addition, D567-T591 also inhibits the generation of kallikrein-activated urokinase, which activates plasminogen to plasmin (IC-50 = 100 nmol/L). Thus, HK-derived peptides may be useful compounds for modulating excessive fibrinolysis and hypotension in sepsis and multiple trauma.

REGISTRY NUMBERS: 9001-01-8: KALLIKREIN; 9039-53-6: UROKINASE; 9001-90-5: PLASMIN

DESCRIPTORS:

MAJOR CONCEPTS: Blood and Lymphatics (Transport and Circulation);

Cardiovascular System (Transport and Circulation); Cell Biology;  
Enzymology (Biochemistry and Molecular Biophysics)  
BIOSYSTEMATIC NAMES: Hominidae--Primates, Mammalia, Vertebrata, Chordata,  
Animalia  
ORGANISMS: human (Hominidae)  
BIOSYSTEMATIC CLASSIFICATION (SUPER TAXA): animals; chordates; humans;  
mammals; primates; vertebrates  
CHEMICALS & BIOCHEMICALS: KALLIKREIN; UROKINASE; PLASMIN  
MISCELLANEOUS TERMS: Research Article; BIOCHEMISTRY AND BIOPHYSICS;  
BLOOD AND LYMPHATICS; CELL SURFACE; CIRCULATORY SYSTEM; FORMATION;  
FORMATION INHIBITION; HIGH MOLECULAR WEIGHT; KALLIKREIN; KININOGEN  
PEPTIDES; UMBILICAL VEIN ENDOTHELIAL CELL; UROKINASE-DEPENDENT PLASMIN  
CONCEPT CODES:  
02508 Cytology and Cytochemistry-Human  
10808 Enzymes-Physiological Studies  
14504 Cardiovascular System-Physiology and Biochemistry  
15004 Blood, Blood-Forming Organs and Body Fluids-Blood Cell Studies  
10064 Biochemical Studies-Proteins, Peptides and Amino Acids  
BIOSYSTEMATIC CODES:  
86215 Hominidae

7/9/2 (Item 2 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.

11019571 BIOSIS NO.: 199799640716  
Physical and biological significance of peptide sequences mediating the  
interaction between high molecular weight kininogen and plasma  
prekallikrein.  
AUTHOR: Colman Robert W(a); Lin Yingzhang; Yan Wuyi; McCrae Keith R; Shenoy  
Shilpa S; Harris Robert B  
AUTHOR ADDRESS: (a)Sol Sherry Thrombosis Res. Cent., Temple Univ. Sch.  
Med., Philadelphia, PA 19140\*\*USA  
JOURNAL: Immunopharmacology 36 (2-3):p193-200 1997  
ISSN: 0162-3109  
RECORD TYPE: Abstract  
LANGUAGE: English

ABSTRACT: HK31 (S565-K595) has previously been shown to encompass the  
binding domain for plasma prekallikrein (PK) within domain 6 of high  
molecular weight kininogen (HK). The complementary binding domain for HK  
within PK is mapped to PK56 (F56-G86), in the Apple 1 domain and to PK266  
(K266-C295) in the Apple 4 domain. Isothermal titration calorimetry  
demonstrated that either PK peptide binds to HK31 in 1:1 stoichiometry.  
Binding of the alternate PK peptide into a ternary complex is facilitated  
nearly 2-fold. Fluorescence emission spectroscopy revealed that only the  
binding of PK56 caused a limited decrease in intrinsic tryptophane  
fluorescence emission intensity of HK31. We conclude that the two PK  
peptides bind to the HK peptide at different sites. To map the minimal  
sequence within HK31, truncated new peptides were tested for their  
ability to compete with HK for binding PK in a cell-free system.  
D567-T591, a 25-residue peptide which contains sufficient structural  
information for binding kallikrein in solution, blocked the binding of  
kallikrein to HK bound to endothelial cells and inhibited PK activation  
to kallikrein and the generation of kallikrein-activated urokinase on  
endothelial cell surfaces. HK-derived peptides could modulate excessive  
fibrinolysis and hypotension in sepsis and multiple trauma.

REGISTRY NUMBERS: 9055-02-1: PREKALLIKREIN; 9001-01-8: KALLIKREIN;  
9039-53-6: UROKINASE; 9001-90-5: PLASMIN  
DESCRIPTORS:

MAJOR CONCEPTS: Biochemistry and Molecular Biophysics; Cardiovascular System (Transport and Circulation); Cell Biology; Endocrine System (Chemical Coordination and Homeostasis); Enzymology (Biochemistry and Molecular Biophysics); Pharmacology

CHEMICALS & BIOCHEMICALS: PREKALLIKREIN; KALLIKREIN; UROKINASE; PLASMIN

MISCELLANEOUS TERMS: Research Article; BINDING DOMAIN; CARDIOVASCULAR SYSTEM; CIRCULATORY SYSTEM; ENDOCRINE SYSTEM; ENDOTHELIAL CELL; ENZYMOLOGY; FIBRINOLYSIS; HIGH-MOLECULAR WEIGHT; HK31; KALLIKREIN; KININOGEN; PEPTIDE SEQUENCES; PHARMACODYNAMICS; PLASMA; PLASMIN; PREKALLIKREIN; S565-K595; UROKINASE

CONCEPT CODES:

02506 Cytology and Cytochemistry-Animal  
10064 Biochemical Studies-Proteins, Peptides and Amino Acids  
10806 Enzymes-Chemical and Physical  
14504 Cardiovascular System-Physiology and Biochemistry  
17020 Endocrine System-Neuroendocrinology (1972- )  
22010 Pharmacology-Cardiovascular System

? s (sepsis or septic?) and "heparin binding"

91872 SEPSIS

108584 SEPTIC?

154 HEPARIN BINDING

S8 0 (SEPSIS OR SEPTIC?) AND "HEPARIN BINDING"

? s lps and "heparin binding"

78158 LPS

154 HEPARIN BINDING

S9 2 LPS AND "HEPARIN BINDING"

? type s9/full/all

9/9/1 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2003 BIOSIS. All rts. reserv.

13292390 BIOSIS NO.: 200100499539

Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof.

AUTHOR: Little Roger G II(a)

AUTHOR ADDRESS: (a)Benicia, CA\*\*USA

JOURNAL: Official Gazette of the United States Patent and Trademark Office

Patents 1246 (2):pNo Pagination May 8, 2001

MEDIUM: e-file

PATENT NUMBER: US 6228834 PATENT DATE GRANTED: May 08, 2001 20010508

PATENT ASSIGNEE: Xoma Corporation PATENT COUNTRY: USA

ISSN: 0098-1133

DOCUMENT TYPE: Patent

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: The present invention provides peptides having an amino acid sequence that is the amino acid sequence of a human bactericidal/permeability-increasing protein (BPI) functional domain or a subsequence thereof, and variants of the sequence or subsequence thereof, having at least one of the BPI biological activities, such as heparin binding, heparin neutralization, LPS binding, LPS neutralization or bactericidal activity. The invention provides peptides and pharmaceutical compositions of such peptides for a variety of therapeutic uses.

DESCRIPTORS:

MAJOR CONCEPTS: Pharmacology

CHEMICALS & BIOCHEMICALS: bactericidal/permeability-increasing protein --human; peptides--biologically active, pharmaceutical

MISCELLANEOUS TERMS: BPI amino acid sequence; BPI biological

activities--LPS binding, LPS neutralization, bactericidal activity, heparin binding, heparin neutralization

9/9/2 (Item 2 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2003 BIOSIS. All rts. reserv.

08865528 BIOSIS NO.: 199396017029

Partial biochemical characterization and purification of IgG2b inducing factor as a new cytokine from synovial fluid of patients with rheumatoid arthritis.

AUTHOR: Abedi-Valugerdi M(a); Ridderstad A; Strom H; Moller G; Moller E

AUTHOR ADDRESS: (a)Dep. Immunol., Arrhenius Lab. for Natural Sci, Stockholm Univ., S-10691 Stockholm\*\*Sweden

JOURNAL: Scandinavian Journal of Immunology 37 (4):p430-436 1993

ISSN: 0300-9475

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: Rheumatoid arthritis synovial fluid (RA-SF) contains a novel biological activity, which selectively induces IgG2b antibody production in lipopolysaccharide (LPS)-activated mouse spleen cells in vitro and in vivo. Our previous studies have shown that this activity is not functionally identical to other well-known cytokines and interleukins. In this study we demonstrate the partial purification and biochemical characterization of the IgG2b inducing activity in RA-SF. Biochemical characterization revealed that the IgG2b inducing activity in RA-SF has the following properties: it is a protein, sensitive to pH gt 11 and lt 4, which is precipitated by 50% of saturated ammonium sulphate and has a molecular weight of 50-70 kDa; it binds to Cibacron-blue and heparin and its activity is not mediated by immunoglobulins or immune complexes, which are present in RA-SF. Biochemical characteristics of the IgG2b inducing activity also differ from other cytokines and interleukins. The term IgG2b inducing factor is proposed for this novel activity.

REGISTRY NUMBERS: 7783-20-2: AMMONIUM SULFATE

DESCRIPTORS:

MAJOR CONCEPTS: Biochemistry and Molecular Biophysics; Blood and Lymphatics (Transport and Circulation); Clinical Immunology (Human Medicine, Medical Sciences); Endocrine System (Chemical Coordination and Homeostasis); Methods and Techniques; Pathology; Physiology; Skeletal System (Movement and Support)

BIOSYSTEMATIC NAMES: Hominidae--Primates, Mammalia, Vertebrata, Chordata, Animalia

ORGANISMS: Hominidae (Hominidae)

BIOSYSTEMATIC CLASSIFICATION (SUPER TAXA): animals; chordates; humans; mammals; primates; vertebrates

CHEMICALS & BIOCHEMICALS: AMMONIUM SULFATE

MISCELLANEOUS TERMS: AMMONIUM SULFATE PRECIPITATION; ANALYTICAL METHOD; CIBACRON-BLUE BINDING; GEL FILTRATION; HEPARIN BINDING; IMMUNOGLOBULIN G2B; MOLECULAR MASS; PH EFFECT

CONCEPT CODES:

10054 Biochemical Methods-Proteins, Peptides and Amino Acids

10064 Biochemical Studies-Proteins, Peptides and Amino Acids

10506 Biophysics-Molecular Properties and Macromolecules

12508 Pathology, General and Miscellaneous-Inflammation and Inflammatory Disease

15008 Blood, Blood-Forming Organs and Body Fluids-Lymphatic Tissue and Reticuloendothelial System

15010 Blood, Blood-Forming Organs and Body Fluids-Other Body Fluids

17002 Endocrine System-General  
 18006 Bones, Joints, Fasciae, Connective and Adipose Tissue-Pathology  
 34508 Immunology and Immunochemistry-Immunopathology, Tissue Immunology  
 10050 Biochemical Methods-General  
 10060 Biochemical Studies-General  
 10068 Biochemical Studies-Carbohydrates  
 10504 Biophysics-General Biophysical Techniques  
 BIOSYSTEMATIC CODES:  
 86215 Hominidae  
 ? ds

Set	Items	Description
S1	0	SE1 OR S3
S2	54	AU='HARRIS ROBERT' OR AU='HARRIS ROBERT B'
S3	36	AU='WOLZ R L' OR AU='WOLZ RL' OR AU='WOLZ RUSSELL' OR AU='WOLZ RUSSELL L'
S4	15	AU='WOLZ G' OR AU='WOLZ G S' OR AU='WOLZ GABRIELLA'
S5	105	S2 OR S3 OR S4
S6	108586	S5 AND SEPSIS OR SEPTIC?
S7	2	S5 AND (SEPSIS OR SEPTIC?)
S8	0	(SEPSIS OR SEPTIC?) AND "HEPARIN BINDING"
S9	2	LPS AND "HEPARIN BINDING"
S10	0	AEARARRAAARAARAARA